Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialCLINICAL PERSPECTIVE

(2016) Akshay S. Desai et al.   Circulation-Heart Failure

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

(2016) Michele Senni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT

(2014) Michel Komajda et al.   EUROPEAN JOURNAL OF HEART FAILURE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial

(2012) Andrew P. Ambrosy et al.   AMERICAN HEART JOURNAL

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

(2012) Mihai Gheorghiade et al.   HEART FAILURE REVIEWS